Publications by authors named "Ari D Panzer"

Claim this Profile
S
Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
A Alex Levine, Ari D Panzer, Teresa L Kauf, Amy K O'Sullivan, Lauren Strand

J Manag Care Spec Pharm· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Ari D Panzer, Michael Ingham, Silas Martin, James D Chambers

J Manag Care Spec Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
James D Chambers, Daniel E Enright, Ari D Panzer, Josh T Cohen, Daniel A Ollendorf

J Manag Care Spec Pharm· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing health plan evidence review practices.
Ari D Panzer, Daniel E Enright, Jen Graff, James D Chambers

J Manag Care Spec Pharm· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' access to 2018 FDA-approved drugs 1 year post approval.
Ari D Panzer, Nikoletta M Margaretos, Naomi Bridger, Mikala C Osani, Rachel C Lai

Am J Manag Care· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of prescriber requirements among US commercial health plans.
Kelly Lenahan, Ari D Panzer, Rebecca Gertler, James D Chambers

J Manag Care Spec Pharm· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in access to hemophilia A treatments in the United States.
Nikoletta M Margaretos, Anisha M Patel, Ari D Panzer, Rachel C Lai, Jennifer Whiteley

J Med Econ· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
NikoLetta M Margaretos, Ari D Panzer, Rachel C Lai, Myrlene Sanon, Efstathios Michalopoulos

J Manag Care Spec Pharm· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited role of patient input in specialty drug coverage policies.
Brittany D'Cruz, Jennifer S Graff, Ari D Panzer, James D Chambers

J Manag Care Spec Pharm· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, Daniel E Enright, James D Chambers

Pharmacoepidemiol Drug Saf· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth and capacity for cost-effectiveness analysis in Africa.
Ari D Panzer, Joanna G Emerson, Brittany D'Cruz, Avnee Patel, Saudamini Dabak

Health Econ· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans.
James D Chambers, Rachel C Lai, Nikoletta M Margaretos, Ari D Panzer, Joshua T Cohen

JAMA· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage.
James D Chambers, Ari D Panzer, Elle F Pope, Jennifer S Graff, Peter J Neumann

Health Aff (Millwood)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in US private health plans' coverage of orphan drugs.
James D Chambers, Ari D Panzer, David D Kim, Nikoletta M Margaretos, Peter J Neumann

Am J Manag Care· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures.
Peter J Neumann, Jordan E Anderson, Ari D Panzer, Elle F Pope, Brittany N D'Cruz

Gates Open Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis